RTS,S malaria vaccine reaches more than 650 000 children in Ghana, Kenya and Malawi through groundbreaking pilot programme


Two years after the launch of a pilot program, more than 1.7 million of the world's first malaria vaccines have been distributed in Ghana, Kenya and Malawi, benefiting more than 650,000 children with additional malaria protection.

A relatively small number of children arrive in this short period, indicating a strong social need for vaccination and the ability of child immunization programs in countries to provide immunization to a new timetable (4 to 2 years of age).

At a time when global progress in malaria control has stalled, the RDS vaccine, s. The protection afforded by malaria, each has the potential to save thousands of lives, when currently recommended malaria control interventions are added. Years.

"Existing pediatric vaccination sites in Kenya, Kenya and Malawi have shown that children can be vaccinated effectively against malaria, some of which do not have pesticide-treated beds or other remedies to prevent malaria, "Dr. K. O. Said Brian, director of Vaccine, Vaccine and Biology. . "This vaccine will be important in distributing the malaria vaccine more evenly and saving many lives."

Director of WHO Global Malaria Program Drs. Point Pedro Alonso said, "Over the past 2 decades, we have achieved shocking results with existing malaria control devices, with over 7 million deaths and 1.5 billion cases." "However, certainly no progress has been made towards the major goals of our global malaria strategy. New tools are urgently needed to get back on track - and malaria vaccines should be an integral part of the general toolkit."

The insights generated by the pilot process would inform WHO's recommendation for widespread vaccine use in sub-Saharan Africa. Global advocates for vaccines and malaria will review RTS data in October 2021 and consider whether the vaccine can be recommended for widespread use.

"In some ways malaria is a lifelong child health emergency - or many lifetimes - in Africa. We appreciate the work of countries that have participated with strong protections for malaria vaccine pilots. The reverse trend," Dr. Akbaka Kalu said. WHO Committee on Tropical and Vector Borne Diseases in the African Region.

Meanwhile, the progress of reducing malaria in the last four years has hit a plateau in the latest World Malaria Report. By 2019, it is estimated that 229 million malaria episodes and 400,000 illnesses will die. More than 90% of malaria deaths occur in Africa - over 265 000 - in young children.

RDS is the only vaccine that can reduce malaria in children, first and foremost, including severe fatal malaria, which requires hospitalization and transfusion of blood. The vaccine is currently being tested in medium and high malaria prone areas, where up to 60% of child seizures to malaria healthcare facilities can reach.

The Malaria Vaccine Implementation Program supports the nationwide RDS vaccine in the child vaccine; And, individually, to evaluate how to approach children with recommended four-dose diet with regular use, severe malaria and life-threatening weaknesses and vaccine safety.

Author's Notes:

Pediatric immunization numbers are based on national management planning reports from Ghana, Kenya and Malawi. These are the expected malaria vaccine levels on 25 April 2021 as the pilot was launched in 2019 and the number of children receiving the first vaccine.

Extensive clinical trials in Sub-Saharan Africa (including large-scale phase 3 trials) have confirmed that RDS, the malaria vaccine, reduces malaria, including fatal malaria in young children.

The RTS vaccine, S / AS01 malaria, has been approved by the respective National Regulatory Authority (NRA) for use in pilot areas of Ghana, Kenya and Malawi and has received positive scientific feedback from the European Drugs Agency (EMA). These regulators agreed in their assessment that the vaccine has an acceptable safety profile and that the benefits of the vaccine are excluded from the risks.

The Malaria Vaccine Implementation Program is coordinated by the WHO and is supported by national and international partners such as PATH, UNICEF and GSK, who provide 10 million doses of the vaccine per pilot.

The WHO and MVIP partners acknowledge the Global Fund's generous support for the fight against AIDS, tuberculosis and malaria and the United Nations.